Nasrat, XX-K you, year links It's the thanks our Thank Investor the March in provide to everyone our available on which Section also ended and filings. is XXXX. on for XXst, K fiscal other sec.gov that filed websites we of as today. Yesterday, elitepharma.com. many calling website and our always is the
get elitepharma.com a If you any from please the through copy sites. yet gone other haven't K the of or usual
context parts the like So financials, review key providing to analysis numbers. insight the today, and of some the of into I'd
my financials comments. as Elite questions shareholders received part of those that have are from we related and always, address followers. do And I'll to comments best my As and
filing which classified the one a point technical the First, filer, of a more of as to as were Elite item this out smaller now is is recent but the prior of changes technical I change effects an change. result company accelerated reporting It's in we opposed to deadlines. in SEC regulations, as want a regulations notable to that
now are the March year-end reports accelerated as after days XXth the old for accelerated XX due to the XX days end annual XX opposed from are XX opposed as days for is or reports to quarter due filers. from XXst regulations days the Quarterly filers. days June So under date. XX regulations
why there's So regulations we reason that the follow. we wondering their the got that SEC with than was and schedule Also night. the shareholders prior few some filed was K it a issue last years new and reporting a from messages had in it with later seemed that's new website
to little the So sorted out the usual. technical that SEC filing obviously. actually with went was But that due have some than a been later issues
year that the year. fiscal So let's start P&L. with were the March compares Revenues year ended million for $X.X the $XX for XXXX million to and XXXX, the XXXX fiscal
$XX.X year. a or that's the as % XXX% increase to million So compared last
increase in three Adderall fiscal So our The be a clearly to during fiscal extended-release Adderall, XXXX year. Dantrolene generic of extent very XXXX at fiscal lesser end XXXX. launched we that The to least and Those immediate-release a Adderall, Adderall. generic for extended-release the launched are generic at largest was No come revenues, revenues well doubt in the these can Elite's dollar increase year as close to the has history. our highest revenues products are as in without that. attributed
So earned The splits. there's manufacturing are revenues remember, distinct those and manufacturing we ship profit streams. the and revenues There's product. consist we revenues, make two our when of
Naltrexone. very generic to extended Adderall; year, in strong drivers XXXX from They've products $XX.X Dantrolene in the a Isradipine this products are prior million million our to or $X.X million those from prior just XXXX. increased immediate increase $X.X Adderall here had It's main three a years. XXX%. and those So and mentioned The and the release I also ones release years existing especially launched
have it our volumes, well that as and personnel, lot lab All we all manufacturing this producing our run as give supply the record job a quality on cylinders continue all You credit to have Covid to shipping volumes to pandemic. record of current ensuring done and a phenomenal during also chain partners. of
an what So achievement, that's quite everybody really has done. remarkable
those even lag a The earn of earn be market. could to the the from natural we or And profits marketing their splits so of other we market on even split are when in when those of parts sell achieved. our to our a market few those manufacture revenues revenues. timing four sales depend into quarters and six are These as sales partners when profit up we quarters in there's
to they're So $X.X XXXX this $X.X million from splits, up in million year. profit
or So million increase $X.X that's a XX%.
notice of just month Adderall there's was the due lower increase during you splits manufacturing compared extended-release launched profit since two is the a between lag last I mentioned as in the rate revenues. timing this especially types of to So revenues the of year. to And the
earning which during ship we quantities they it into sell product, milestone split a as launched is So earned March Lannett will but other profit the revenues XXXX, the be we our as than when $XXX,XXX launched the marketing market. partner
coming the So launch to few a online. after it for the takes profit quarters product start splits
year, earlier XXXX. fiscal release launched and fiscal So immediate Adderall in Dantrolene the were
few split the extended year. right extended impact the release the Adderall So contribution And impacted not additional on to of they the from splits they've the because to Adderall But those at as profit profit we do positively yet split end expect were amphetamine, revenues release online start already started quarters. profit has next revenues. over launched come
put the $X.X profits a from $XX to put single year. you up increases million going revenues revenues million and get manufacturing total in you together, in So both
important as has version before new moving launched as the to think in of market. keep release release I it's relatively mind and that on, They're So Adderall Adderall been both well in Dantrolene. the immediate extended just
for growth there's in the great room Our these still done a marketing products, partner has with future. of all job but
went come million expenses, year last $X.X So and to decrease million $X.X P&L, down million moving we down a That's XXXX. the year to fiscal from or which this XXXX development research XX%. $X.X
it always things in said comes to always when expenses. mind I've there keep R&D two are to As
R&D is the the company. spend spent at launched the we part that that XXXX. to fiscal XXXX, were early year went that A we and the part end this went large products pharmaceutical in million that XXXX $X.X is the in million in to of lifeblood any they of the very product also First XXXX $X.X launched of of
from to years we we spend need clearly financials money That's everybody our the So this. and revenues. to before two with get what show happens three anywhere
and R&D specific decreased. to the you a just clinical as it the what Certain just in nature important thing us. activities other that's spend and activities also activities cost expenses result during regards that spend our case development decreased, has on as is that it keep of amounts The trials, And engaged mind mean is more amount have as spent they the to are the often product R&D changes R&D efforts period. doesn't with a in of than the such others; spent cost with in particular because
the based fluctuate the R&D activities expect usual of and the forward upon continue we levels Our specific nature costs going conducted. to efforts at
a important in the existing introduction revenues We most from products. the the milestone was greatly products summary, any been and growth revenues that for prior of year record year. have earned launched achieved importantly, year products during in exceeded fiscal So Elite. from XXXX new We three and
in growing still All our a year continued a XXXX, fiscal and of and these shareholder had which did challenges in by for we we concern year we have major regulatory fiscal underlying in challenges. consistency work this But our we are competitive us seek further those value. XXXX. but industry financials significant make strides during us faced always achieved this regular last meeting our our showing remain. achieving there's and growth. our that significant have don't which signs and in for in out of We year, condition improvement towards cut financial, improved We, the opinion everyone fundamentals We'll
to Nasrat and So in CEO an Mr. his comments. update Hakim Chairman would like give our now
